Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | AOC3 | Q16853 | 10/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17674539 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AAOC3NPC1RAB9A | |
| SCHEMBL2612387 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AAOC3NPC1RAB9A | |
| SCHEMBL3933173 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AAOC3NPC1RAB9A | |
| SCHEMBL1939115 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2AAOC3NPC1RAB9A | |
| SCHEMBL17977308 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2AAOC3NPC1RAB9A | |
| SCHEMBL11202231 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2AAOC3NPC1RAB9A | |
| SCHEMBL307301 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2KMT2AAOC3NPC1RAB9A | |
| SCHEMBL972734 | 0.82 | AOC3 (0.85) | SMN1; SMN2KMT2AAOC3MAOB | |
| SCHEMBL14134478 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2AAOC3NPC1RAB9A | |
| SCHEMBL10864306 | 0.82 | AOC3 (0.60) | SMN1; SMN2KMT2AAOC3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997024-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9278954-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-08 | — | — | US | disclosed |
| WO-2014184104-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | WO | disclosed |
| US-20140343083-A1 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1847543-A1 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343083-A1 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | ACACB, PC, ACACA | SMN1; SMN2 4174/4885KMT2A 1104/4885AOC3 2552/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | SMN1; SMN2 1736/4885KMT2A 3750/4885AOC3 2029/4885 |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | SMN1; SMN2 833/4885KMT2A 4217/4885AOC3 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.